Table 5.
Hazard ratios for DFS and DSS in stage Ⅱ‐III GAC patients receiving adjuvant chemotherapy or not according to α‐SMA and CD66b coexpression patterns
| Factor | Patients | % | Adjuvant chemotherapeutic (yes vs no) | |||
|---|---|---|---|---|---|---|
| DFS | DSS | |||||
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | |||
| α‐SMA & CD66b | 183 | 0.482 (0.337‐0.689) | <.001 | 0.476 (0.333‐0.681) | <.001 | |
| α‐SMAlowCD66blow | 65 | 35.5 | 0.260 (0.124‐0.542) | <.001 | 0.258 (0.124‐0.538) | <.001 |
| α‐SMAlowCD66bhigh | 31 | 16.9 | 0.694 (0.298‐1.613) | .396 | 0.662 (0.285‐1.538) | .337 |
| α‐SMAhighCD66blow | 28 | 15.3 | 0.736 (0.303‐1.784) | .497 | 0.694 (0.298‐1.613) | .476 |
| α‐SMAhighCD66bhigh | 59 | 32.2 | 0.643 (0.367‐1.125) | .122 | 0.650 (0.371‐1.139) | .132 |
Abbreviations: α‐SMA, α‐smooth muscle actin; CI, confidence interval; DFS, disease‐free survival; DSS, disease‐specific survival; GAC, gastric adenocarcinoma; HR, hazard ratio.
P < .05 is considered statistically significant (bold).